St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
- Fundraising
St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
- Fundraising
IMPAACT 2017/MOCHA end-of-study results publish
The Food and Drug Administration approved an all-injectable antiretroviral regimen (cabotegravir and rilpivirine) in adolescents aged 12-17 years with HIV in 2022. The week 96 and end-of-trial study data from the clinical trial that led to that approval (International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT 2017)/More Options for Children and Adolescents (MOCHA)) were recently published in Lancet Child & Adolescent Health.
Aditya Gaur, MD, served as co-chair of the IMPAACT 2017/MOCHA trial that led to the approval of an all-injectable antiretroviral regimen in adolescents aged 12-17 years.
The data, collected from 18 sites in Botswana, South Africa, Thailand, Uganda and the United States, demonstrated the safety, acceptability and tolerability, antiviral activity, and pharmacokinetics of the regimen in this age group, extending the data from week 48, which were published earlier this year.
The data confirm the sustained safety and effectiveness of the treatment and will continue to help shape treatment worldwide.
“Hundreds of colleagues from around the world teamed up to design and conduct this clinical trial. We are proud to share what these first adolescents to receive this all-injectable HIV treatment regimen and their families taught us,” said Aditya Gaur, MD, co-chair of IMPAACT 2017 and Division of HIV and Translational Medicine director, Department of Infectious Diseases. “One study participant remarked, ‘I would much rather have these shots than win a lottery,’ and in many ways, this remark says it all for all who made this work possible.”